{"type":"trials","record":{"id":41834,"source_id":"clinicaltrials-gov","external_id":"NCT06875245","title":"Comparing Efficacy of 8-Week and 12-Week Faricimab Initial Follow-Up Treatment Intervals","brief_summary":"This is a prospective, randomized study that compares 8-week and 12-week follow-up intervals after the 4 monthly injections in the loading phase. Patients with active CNV confirmed on optical coherence tomography (OCT) and OCT angiography (OCTA) will be randomized into two groups and followed for 44 to 56 weeks. Patients in the first group will receive 4 injections of faricimab every 4 weeks, with the next visit and injection after 8 weeks, followed by a treat-and-extend regimen with a minimal interval of 8 weeks and a maximal interval of 16 weeks. Patients in the second group will also receive 4 loading doses with the next visit after an extended 12-week interval. Following treatment, patients in this group will be on the same treat-and-extend regimen as patients in the first group. The study will compare best corrected visual acuity (BCVA), central retinal thickness (CRT) on OCT, and the number of injections between both groups.","overall_status":"Recruiting","phases":["PHASE4"],"study_type":"INTERVENTIONAL","sponsor":"Faculty Hospital Kralovske Vinohrady","enrollment":100,"countries":["Czechia"],"start_date":"2023-03-31","completion_date":"2026-04-01","last_update_date":"2025-03-13","source_url":"https://clinicaltrials.gov/study/NCT06875245","editorial_summary":"A registered PHASE4 study indexed because it matched monitored longevity research terms. Registry status: Recruiting. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":null,"age_range":null,"comparator":null,"organization":"Faculty Hospital Kralovske Vinohrady","interventions":["Faricimab Injection"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Change in CRT — from baseline up to 56 weeks","Patients with intraretinal or subretinal fluid or serous pigment epithelium detachment after loading — From baseline to…","Change from baseline in BCVA — From baseline up to 56 weeks","Presence of fluid — From baseline up to 56 weeks","Number of injections — From baseline up to 56 weeks","Treatment interval — From baseline up to 56 weeks"],"design_description":"RANDOMIZED · PARALLEL · TREATMENT · NONE","source_has_results":false},"controlled_terms":["Wet Age-related Macular Degeneration","Faricimab Injection"],"relevance_confidence":60,"source_quality_score":100,"freshness_score":65,"publication_state":"published","match_explanation":"Source terminology contains: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct06875245","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2023-03-31 to 2026-04-01","comparator":null,"confidence":"structured-source","population":"ALL","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.878Z","intervention":["Faricimab Injection"],"participants":100,"study_design":"RANDOMIZED · PARALLEL · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE4","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Change in CRT — from baseline up to 56 weeks","Patients with intraretinal or subretinal fluid or serous pigment epithelium detachment after loading — From baseline to…","Change from baseline in BCVA — From baseline up to 56 weeks","Presence of fluid — From baseline up to 56 weeks","Number of injections — From baseline up to 56 weeks","Treatment interval — From baseline up to 56 weeks"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Source terminology contains: age-related macular degeneration.","Source terminology supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["controlled terminology","controlled context","study type"],"relevance_score":60,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/41834","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}